مقایسه‌ی اثر صافی‌های High-Flux و Low-Flux بر کفایت همودیالیز در بیماران مبتلا به بیماری کلیوی مرحله‌ی نهایی تحت همودیالیز

نوع مقاله : مقاله های پژوهشی

نویسندگان

1 دستیار، گروه داخلی، دانشکده‌ی پزشکی، دانشگاه علوم پزشکی شهرکرد، شهرکرد، ایران

2 استادیار، گروه داخلی، دانشکده‌ی پزشکی، دانشگاه علوم پزشکی شهرکرد، شهرکرد، ایران

3 دانشیار، گروه آمار زیستی، دانشکده‌ی بهداشت، دانشگاه علوم پزشکی شهرکرد، شهرکرد، ایران

4 استاد، گروه داخلی، دانشکده‌ی پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران

چکیده

مقدمه: همودیالیز رایج‌ترین روش درمان جایگزینی نارسایی مزمن کلیه به شمار می‌رود و دیالیز ناکافی سبب افزایش مرگ و میر بیماران می‌شود؛ لذا، کفایت دیالیز در این بیماران از اهمیت زیادی برخوردار است. این مطالعه، به منظور مقایسه‌ی کفایت همودیالیز در صافی‌های High-flux و Low-flux در یک مرکز دیالیز انجام گردید و رابطه‌ی آن با برخی شاخص‌های آزمایشگاهی بیماران تحت همودیالیز بررسی شد.روش‌ها: پژوهش پیش رو، به صورت کار آزمایی بالینی تصادفی شده با استفاده از تفاوت‌های صافی‌ها و همچنین، اثر اولترافیلتراسیون در دفع سموم بین 42 نفر از بیماران تحت همودیالیز با صافی‌های Low-flux و High-flux انجام گردید. بیماران مرحله‌ی نهایی بیماری مزمن کلیه (End-stage renal disease یا ESRD) با میزان اولترافیلتراسیون بیشتر از 3 لیتر، با قرار گیری در 2 گروه به صورت متقاطع در 2 ماه تحت همودیالیز با صافی‌های High-flux و Low-flux قرار گرفتند و شاخص‌های لازم جهت اندازه‌گیری Kt/V در هر بار همودیالیز و سایر اندکس‌های آزمایشگاهی در ابتدا و انتهای هر ماه در آن‌ها مورد ارزیابی قرار گرفت. سپس، تجمیع نهایی داده‌های بیماران در این دو ماه مقایسه شد و یافته‌ها با استفاده از نرم‌‌افزار SPSS، تحلیل گردید.یافته‌ها: تفاوت آماریِ معنی‌داری در کفایت دیالیز، بین دو گروه دیده شد. یافته‌های تجمیعی برای بیماران تحت همودیالیز با صافی High-flux و Low-flux نشان داد که اگر چه در هر دو گروه، کفایت دیالیز در حد مطلوب از نظر استانداردهای تعریف شده برای کفایت دیالیز بود ولی Kt/V به طور معنی‌داری در همودیالیز با صافی High-flux نسبت به همودیالیز با صافی Low-flux بیشتر بود (013/0 = P).نتیجه‌گیری: این مطالعه نشان داد که صافی‌های High-flux، نسبت به Low-flux، در حجم‌های بالاتر از 3 لیتر اولترافیلتراسیون، در افزایش میانگین کفایت دیالیز نقش بیشتری داشتند؛ پیشنهاد ما برای پژوهش‌های آتی، ارزیابی تأثیر استفاده‌ی طولانی مدت صافی‌های High-flux در بیماران تحت همودیالیز بر کفایت دیالیز، بهبود کیفیت زندگی و کاهش میزان بستری آن‌ها و اثر آن در کاهش هزینه‌های درمانی بیماران می‌باشد؛ تا بدین وسیله، هزینه- فایده (Cost-benefit) استفاده‌ی دراز مدت از صافی‌های High flux نیز سنجیده شود.

کلیدواژه‌ها


عنوان مقاله [English]

Comparison of High-Flux and Low-Flux Hemodialysis Filters on Hemodialysis Adequacy in Under-Hemodialysis Patients with End-Stage Renal Disease

نویسندگان [English]

  • Hamid Nasri 4
  • Mohadeseh Pour-Pouneh 1
  • Saeed Mardani 2
  • Soleiman Kheiri 3
1 Resident, Department of Internal Medicine, School of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran
2 Assistant Professor, Department of Internal Medicine, School of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran
3 Associate Professor, Department of Biostatics, School of Health, Shahrekord University of Medical Sciences, Shahrekord, Iran
4 Professor, Department of Nephrology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
چکیده [English]

Background: Hemodialysis is the most common alternative therapy in chronic renal failure and inadequate dialysis increases the mortality of patients; thus, the dialysis adequacy in these patients is important. This study aimed to compare the adequacy if hemodialysis high-flux and low-flux filters in Hospital Dialysis Centers of Shahrekord University of Medical Sciences, Iran, and assess its relation to other indices for patients with chronic and end-stage renal disease (ESRD).Methods: In a randomized clinical trial, 42 patients were performed with low-flux and high-flux filters. So, the patients with end-stage chronic kidney disease, with the rate of ultrafiltration of more than 3 liters, in the two cross groups underwent hemodialysis with high- and low-flux filters in 2 months. The indicators for measuring the Kt/V in each dialysis and other lab indices at the beginning and the end of each month were measured and compared using SPSS software.Findings: At the end of the intervention, significant difference in adequacy of dialysis was observed between the two groups of high- and low-flux filtration. Although, both groups of patients had adequacy of dialysis in terms of defined standards, but the findings showed that Kt/V in hemodialysis significantly was lower in high-flux group (P = 0.013).Conclusion: This study showed that the high-flux filters in higher volumes of 3 liters of ultrafiltration, increases the average dialysis adequacy more than the low-flux filters. We suggest future studies to assess the impact of long-term use of high-flux filters on dialysis efficacy, improved quality of life and reduced hospitalization rate in hemodialysis patients and its effect on reducing healthcare costs; patients are thereby cost-benefited in using high-flux filters for long term.

کلیدواژه‌ها [English]

  • End-stage renal disease
  • Dialysis
  • Ultrafiltration
  1. Beladi Mousavi SS, Tamadon MR, Nasri H, Ardalan MR. Bone enumerates as a new endocrine organ interacted in chronic kidney disease and mineral and bone disorders. J Parathyr Dis 2014; 2(2): 67-8.
  2. Malleshappa P, Shah BV. Prevalence of chronic kidney disease and the incidence of acute kidney injury in patients with coronary artery disease. J Nephropharmacol 2015; 4(2): 49-54.
  3. Ghaderian SB, Beladi-Mousavi SS. The role of diabetes mellitus and hypertension in chronic kidney disease. J Renal Inj Prev 2014; 3(4): 109-10.
  4. Gheissari A. Chronic kidney disease and secondary hyperparathyroidism in children. J Parathyr Dis 2014; 2(1): 41-4.
  5. Said S, Hernandez GT. The link between chronic kidney disease and cardiovascular disease. J Nephropathol 2014; 3(3): 99-104.
  6. Nasri H. Comment on; Post-infectious glomerulonephritis presenting as acute renal failure in a patient with Lyme disease. J Renal Inj Prev 2014; 3(1): 35-6.
  7. Hajivandi A, Amiri M. World Kidney Day 2014: Kidney disease and elderly. J Parathyr Dis 2014; 2(1): 3-4.
  8. Mardani S, Nasri H. Catastrophic antiphospholipid syndrome presented with sudden renal failure and history of long-lasting psychosis and hypertension in a 42 years old women. J Nephropathol 2013; 2(2): 110-3.
  9. Junaid Nazar CM, Kindratt TB, Ahmad SM, Ahmed M, Anderson J. Barriers to the successful practice of chronic kidney diseases at the primary health care level; a systematic review. J Renal Inj Prev 2014; 3(3): 61-7.
  10. Tamadon MR, Ardalan MR, Nasri H. World Kidney Day 2013; acute renal injury; a global health warning. J Parathyr Dis 2013; 1(2): 27-8.
  11. Assadi F. Psychological impact of chronic kidney disease among children and adolescents: Not rare and not benign. J Nephropathol 2013; 2(1): 1-3.
  12. Ghaderian SB, Beladi Mousavi SS. Relationship between parathyroid hormone and anemia in uremic patients. J Parathyr Dis 2014; 2(1): 39-40.
  13. Hernandez GT, Nasri H. World Kidney Day 2014: increasing awareness of chronic kidney disease and aging. J Renal Inj Prev 2014; 3(1): 3-4.
  14. Nasri H. Association of serum lipoprotein (a) with hypertension in diabetic patients. Saudi J Kidney Dis Transpl 2008; 19(3): 420-7.
  15. Nasri H. Elevated serum parathyroid hormone is a heart risk factor in hemodialysis patients. J Parathyr Dis 2013; 1(1): 13-4.
  16. Kari J. Epidemiology of chronic kidney disease in children. J Nephropathol 2012; 1(3): 162-3.
  17. Nasri H, Yazdani M. The relationship between serum LDL-cholesterol, HDL-cholesterol and systolic blood pressure in patients with type 2 diabetes. Kardiol Pol 2006; 64(12): 1364-8.
  18. Han Y, Zhu G, Han L, Hou F, Huang W, Liu H, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol 2014; 63(1): 62-70.
  19. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1): S1-266.
  20. Nazar CMJ, Bashir F, Izhar S, Ahmed SA. Does frequent hemodialysis regimen result in regression of left ventricular mass compared to conventional hemodialysis? J Nephropharmacol 2015; 4(1): 37-41.
  21. Levey AS, de Jong PE, Coresh J, El NM, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80(1): 17-28.
  22. Beladi-Mousavi SS, Faramarzi M. Calcimimetic agents in the management of secondary hyperparathyroidism among patients with end-stage renal disease; a review article. J Parathyr Dis 2015; 3(1): 12-9.
  23. Depner TA. Uremic toxicity: urea and beyond. Semin Dial 2001; 14(4): 246-51.
  24. Nasri H. The awareness of chronic kidney disease and aging; the focus of world kidney day in 2014. J Nephropharmacol 2014; 3(1): 1-2.
  25. Hsu CY, Vittinghoff E, Lin F, Shlipak MG. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004; 141(2): 95-101.
  26. Heidari M, Mardani S, Baradaran A. Correlation of serum parathyroid hormone with pulmonary artery pressure in non-diabetic regular hemodialysis patients. J Parathyr Dis 2014; 2(2): 78-80.
  27. Tamadon MR. Effect of hemodialysis fluid cooling uremic pruritus in hemodialysis patients. J Nephropharmacol 2012; 1(2): 27-8.
  28. Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: applications and implications. Am J Kidney Dis 2009; 53(3 Suppl 3): S4-16.
  29. Einollahi B, Motalebi M. Is Quality of life among hemodialysis patients different in various countries? J Parathyr Dis 2014; 2(2): 63-4.
  30. Nasri H, Rafieian-Kopaei M. Significant difference of serum 25-hydroxyvitamin D level in male hemodialysis patients with our without diabetes; a single center study. J Nephropharmacol 2012; 1(2): 15–6.
  31. United States Renal Data System, USRDS 2010 Annual Data Report. Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2010.
  32. Nazar CMJ, Anderson J. Extent of malnutrition in end-stage renal disease patients. J Nephropharmacol 2014; 3(2): 27-8.
  33. Nasri H, Rafieian-Kopaei M. Parathyroid hormone in renal transplanted recipients; a single center study. J Nephropharmacol 2013; 2(1): 3-4.
  34. Gomez CG, Valido P, Celadilla O, Bernaldo de Quiros AG, Mojon M. Validity of a standard information protocol provided to end-stage renal disease patients and its effect on treatment selection. Perit Dial Int 1999; 19(5): 471-7.
  35. Tamadon MR. Secondary hyperparathyroidism and chronic kidney disease. J Parathyr Dis 2013; 1(1): 15-6.
  36. Nasri H, Baradaran A. Association of serum lipoprotein(a) with ultrasonographically determined early atherosclerotic changes in the carotid and femoral arteries in kidney transplanted patients. Transplant Proc 2004; 36(9): 2683-6.
  37. Maesaka JK, Sodam B, Palaia T, Ragolia L, Batuman V, Miyawaki N, et al. Prostaglandin D2 synthase: Apoptotic factor in alzheimer plasma, inducer of reactive oxygen species, inflammatory cytokines and dialysis dementia. J Nephropathol 2013; 2(3): 166-80.
  38. Nasri H, Rafieian-Kopaei M. Serum anti-hepatitis B surface antigen in hemodialysis patients. J Nephropharmacol 2012; 1(1): 3-5.
  39. Boostani H, Ghorbani A, Heydarazadzadeh M. The comparison of general health status between hemodialysis and kidney transplant patients in university hospitals of Ahvaz, Iran. J Renal Inj Prev 2014; 3(1): 27-30.
  40. Amiri M, Nasri H. Secondary Hyperparathyroidism in chronic kidney disease patients; current knowledge. J Parathyr Dis 2014; 2(1): 1-2.
  41. Asl MK, Nasri H. Prevalence of Helicobacter pylori infection in maintenance hemodialysis patients with non-ulcer dyspepsia. Saudi J Kidney Dis Transpl 2009; 20(2): 223-6.
  42. Baradaran A, Nasri H, Rafieian-Kopaei M. Oxidative stress and hypertension: Possibility of hypertension therapy with antioxidants. J Res Med Sci 2014; 19(4): 358-67.
  43. Nasri H. Hypertension and renal failure with right arm pulse weakness in a 65 years old man. J Nephropathol 2012; 1(3): 130-3.
  44. Rafieian-Kopaei M, Nasri H. Serum lipoprotein (a) and atherosclerotic changes in hemodialysis patients. J Renal Inj Prev 2013; 2(2): 47-50.
  45. Mubarak M, Nasri H. What nephrolopathologists need to know about antiphospholipid syndrome-associated nephropathy: Is it time for formulating a classification for renal morphologic lesions? J Nephropathol 2014; 3(1): 4-8.
  46. Beladi Mousavi SS, Tamadon MR, Nasri H, Ardalan MR. Impact of parathyroid hormone on pulmonary artery pressure in hemodialysis patients. J Parathyr Dis 2014; 2(2): 71-2.
  47. Mowlaie M, Nasri H. Close association of arterial plaques with left ventricular hypertrophy and ejection fraction in hemodialysis patients. J Nephropharmacol 2014; 3(1): 9-12.
  48. Nasri H. Sudden onset of renal failure requiring dialysis associated with large B-cell lymphoma of colon. J Nephropathol 2012; 1(3): 202-6.
  49. Nasri H, Baradaran HR. Lipids in association with serum magnesium in diabetes mellitus patients. Bratisl Lek Listy 2008; 109(7): 302-6.
  50. Nasri H. Helicobacter pylori infection and its relationship to plasma magnesium in hemodialysis patients. Bratisl Lek Listy 2007; 108(12): 506-9.
  51. Himmelfarb J, Ikizler TA. Hemodialysis. N Engl J Med 2010; 363(19): 1833-45.
  52. Daugirdas JT, Blake PG, Ing TS. Handbook of Dialysis. 4th ed. Philadelphia, PA; 2006.
  53. Rafieian-Kopaei M, Nasri H. Association of serum lipids with levels of leptin in hemodialysis patients. J Nephropharmacol 2013; 2(2):17-20.
  54. Nasri H, Baradaran A. Correlation of serum magnesium with dyslipidemia in maintenance hemodialysis patients. Acta Medica (Hradec Kralove) 2004; 47(4): 263-5.
  55. Rastegari E, Nasri H. Association of serum leptin with serum C-reactive protein in hemodialysis patients. J Nephropharmacol 2012; 1(2): 19-21.
  56. Nasri H, Kheiri S. Effects of diabetes mellitus, age, and duration of dialysis on parathormone in chronic hemodialysis patients. Saudi J Kidney Dis Transpl 2008; 19(4): 608-13.
  57. Santoro A, Conz PA, De C, V, Acquistapace I, Gaggi R, Ferramosca E, et al. Mid-dilution: the perfect balance between convection and diffusion. Contrib Nephrol 2005; 149: 107-14.
  58. Cronin RE, Henrich WL. Kt/V and the adequency of hemodialysis. Uptodate [Online]. [cited 2011 Mar 18]; Available from: URL: http://cursoenarm.net/UPTODATE/contents/mobipreview.htm?17/53/18257?source=see_link
  59. Sherman RA, Cody RP, Rogers ME, Solanchick JC. Accuracy of the urea reduction ratio in predicting dialysis delivery. Kidney Int 1995; 47(1): 319-21.
  60. Soleimani AR, Tamddon MR, Mianehsaz E, Salami M, Akbari H. A study about the effect of ultrafiltration's increasing on the clearance of middle molecules in low-flux hemodialysis. Feyz 2006; 10(3): 22-7. [In Persian].
  61. Moslem AR, Naghavi M, Basiri Moghadam M, Gharacheh M, Basiri Moghadam K. Assessing the adequacy of dialysis and its relationship with kind of filter in patient under hemodialysis referred to 22-Bahman hospital of Gonabad. Horizon Med Sci 2008; 14(2): 20-3. [In Persian].
  62. Makar SH, Sawires HK, Farid TM, Ali WM, Schaalan M. Effect of high-flux versus low-flux dialysis membranes on parathyroid hormone. Iran J Kidney Dis 2010; 4(4): 327-32.
  63. Makar SH, Sawires HK, Farid TM, Ali WM, Schaalan M. Effect of high-flux versus low-flux dialysis membranes on parathyroid hormone. Iran J Kidney Dis 2010; 4(4): 327-32.
  64. Rahimi Z, Moradi M, Nasri H. A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy. J Res Med Sci 2014; 19(11): 1090-8.